Adherence to lipid-lowering treatment: The patient perspective

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 805-814

  Casula, Manuela ^a   Tragni, Elena ^a   Catapano, Alberico Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Health behavior; Hyperlipidemia drug therapy; Medication adherence; Patient preference

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; UBIDECARENONE;

ALTERNATIVE MEDICINE; CARDIOVASCULAR DISEASE; COMORBIDITY; DIET; DOCTOR PATIENT RELATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; HEALTH BELIEF; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; LIFESTYLE; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MOTIVATION; MUSCLE DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PREFERENCE; PERCEPTION; POLYPHARMACY; PRACTICE GUIDELINE; PROTEIN DEPLETION; REVIEW;

EID: 84886012952     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S29092     Document Type: Review

References (83)

1. World Health Organization. Global Status Report on Noncommunicable Diseases. Geneva: World Health Organization; 2010. Available from: http://www.who.int/nmh/publications/ncd_report2010/en/. Accessed October 15, 2012.
2. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60(4):109-114.
3. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; for EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929-940.
4. Straka RJ, Taheri R, Cooper SL, Tan AW, Smith AC. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy. 2001;21(7):818-827.
5. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006;12(Suppl 15):S405-S411.
6. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-342.
7. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009;10(18):2973-2985.
8. Helin-Salmivaara A, Lavikainen PT, Korhonen MJ, et al. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care. 2010;16(2):116-122.
9. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010; 17(3):CD004371.
10. Sabaté E; World Health Organization, Noncommunicable Diseases and Mental Health Cluster. Adherence to Long-term Therapies: Policy for Action: Meeting Report, 4-5 June 2001. Geneva: World Health Organization; 2001. Available from: http://apps.who.int/iris/handle/10665/66984. Accessed October 15, 2012.
11. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
12. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6): 1074-1090; discussion 1073.
13. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004;42(7):649-652.
14. Cramer JA, Spilker B, editors. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press; 1991.
15. Garfield S, Clifford S, Eliasson L, Barber N, Wilson A. Suitability of measures of self-reported medication adherence for routine clinical use: A systematic review. BMC Med Res Methodol. 2011; 11:149.
16. Corrao G, Conti V, Merlino L, Catapano AL, Mancia G. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther. 2010;32(2):300-310.
17. Lemstra M, Blackburn D. Nonadherence to statin therapy: discontinuation after a single fill. Can J Cardiol. 2012;28(5):567-573.
18. Perreault S, Blais L, Dragomir A, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61(9):667-674.
19. Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy-experience in Australia 2006-2010. Aust Fam Physician. 2011; 40(5):319-322.
20. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther. 2008;30 Pt 2:2228-2240.
21. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90(9):1065-1066.
22. Korhonen MJ, Helin-Salmivaara A, Huupponen R. Dynamics of long-term statin therapy. Eur J Clin Pharmacol. 2011;67(9):925-931.
23. Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14(6):388-392.
24. Mauskop A, Borden WB. Predictors of statin adherence. Curr Cardiol Rep. 2011;13(6):553-558.
25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
26. Mechanic D, editor. The Growth of Bureaucratic Medicine: An Inquiry into the Dynamics of Patient Behavior and the Organization of Medical Care. New York: Wiley; 1976.
27. Meichenbaum D, Turk DC. Facilitating Treatment Adherence: A Practitioner's Guidebook. New York: Plenum Press; 1987.
28. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-645.
29. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196-202.
30. Haynes RB, Sackett DL, editors. Compliance with Therapeutic Regimens. Baltimore: Johns Hopkins University Press; 1976.
31. McGinnis B, Olson KL, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother. 2007;41(11):1805-1811.
32. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555-567.
33. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q. 1984;11(1):1-47.
34. Durack-Bown I, Giral P, d'Ivernois JF, et al. Patients' and physicians' perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract. 2003;53(496):851-857.
35. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18): 1458-1462.
36. Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4-10.
37. Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs. 2006;6(6): 383-391.
38. Bardel A, Wallander MA, Svärdsudd K. Factors associated with adherence to drug therapy: a population-based study. Eur J Clin Pharmacol. 2007;63(3):307-314.
39. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471-1477.
40. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461.
41. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847-852.
42. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract. 2002;19(6):596-604.
43. Erhardt L, Hobbs FD. Public perceptions of cardiovascular risk in five European countries: the react survey. Int J Clin Pract. 2002; 56(9):638-644.
44. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208-215.
45. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press; 1991.
46. Gadkari AS, McHorney CA. Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res. 2012;12:98.
47. Unni EJ, Farris KB. Unintentional non-adherence and belief in medicines in older adults. Patient Educ Couns. 2011;83(2):265-268.
48. Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10(3):135-140.
49. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychology and Health. 1999;14(1):1-24.
50. Khanderia U, Townsend KA, Erickson SR, Vlasnik J, Prager RL, Eagle KA. Medication adherence following coronary artery bypass graft surgery: assessment of beliefs and attitudes. Ann Pharmacother. 2008;42(2):192-199.
51. Reaume KT, Erickson SR, Dorsch MP, et al. Effects of cerivastatin withdrawal on statin persistence. Ann Pharmacother. 2008;42(7): 956-961.
52. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25): 3143-3421.
53. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207-213.
54. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80(1):106-107.
55. Grundy SM, Cleeman JI, Merz CN, et al; for National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
56. Catapano AL. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr Med Res Opin. 2009;25(2):431-447.
57. Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814-822.
58. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. Med Gen Med. 2007; 9(3):58.
59. Gialamas A, Aylward P, Vanlint S, Stocks NP. Cholesterol lowering medication-patients' knowledge, attitudes and experiences. Aust Fam Physician. 2011;40(7):519-522.
60. Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25(10):885-892.
61. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
62. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004;164(21):2343-2348.
63. Natarajan N, Putnam RW, Yip AM, Frail D. Family practice patients' adherence to statin medications. Can Fam Physician. 2007;53(12): 2144-2145.
64. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421.
65. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.
66. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834.
67. Muls E, De Bbacker G, De Bacquer D, Brohet M, Heller F; for LIPI-WATCH Investigators. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest. 2000;19(3):219-229.
68. Lablanche JM. Achieving LDL-C target levels: the role of statins. Curr Med Res Opin. 2001;16(4):285-295.
69. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100(6): 605-610.
70. Catapano AL, Reiner Z, De Backer G, et al; for European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46.
71. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm. 2005;62(14):1468-1475.
72. Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One. 2011;6(12):e28124.
73. Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: A survey in real life. Nutr Metab Cardiovasc Dis. Epub June 28, 2012.
74. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6): 403-414.
75. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393-403.
76. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10(3):373-387.
77. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30(8):669-675.
78. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
79. Helin-Salmivaara A, Korhonen MJ, Alanen T, Huupponen R. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland. J Clin Pharm Ther. 2012;37(1):58-64.
80. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23): 3028-3035.
81. Simpson M, Buckman R, Stewart M, et al. Doctor-patient communication: the Toronto consensus statement. BMJ. 1991;303(6814):1385-1387.
82. Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ. 1995;152(9):1423-1433.
83. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25(6):445-451.